0HB0 Stock Overview
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Agios Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$31.59 |
52 Week High | US$35.35 |
52 Week Low | US$20.13 |
Beta | 0.86 |
1 Month Change | 6.76% |
3 Month Change | 36.60% |
1 Year Change | 44.83% |
3 Year Change | -43.39% |
5 Year Change | -51.82% |
Change since IPO | -60.86% |
Recent News & Updates
Recent updates
Shareholder Returns
0HB0 | GB Biotechs | GB Market | |
---|---|---|---|
7D | 8.0% | -0.2% | 2.3% |
1Y | 44.8% | -29.5% | 0.6% |
Return vs Industry: 0HB0 exceeded the UK Biotechs industry which returned -29.8% over the past year.
Return vs Market: 0HB0 exceeded the UK Market which returned 0.3% over the past year.
Price Volatility
0HB0 volatility | |
---|---|
0HB0 Average Weekly Movement | 7.4% |
Biotechs Industry Average Movement | 6.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0HB0's share price has been volatile over the past 3 months.
Volatility Over Time: 0HB0's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 385 | Brian Goff | www.agios.com |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.
Agios Pharmaceuticals, Inc. Fundamentals Summary
0HB0 fundamental statistics | |
---|---|
Market cap | US$1.79b |
Earnings (TTM) | -US$352.09m |
Revenue (TTM) | US$26.82m |
66.3x
P/S Ratio-5.1x
P/E RatioIs 0HB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0HB0 income statement (TTM) | |
---|---|
Revenue | US$26.82m |
Cost of Revenue | US$298.41m |
Gross Profit | -US$271.58m |
Other Expenses | US$80.50m |
Earnings | -US$352.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | -6.27 |
Gross Margin | -1,012.50% |
Net Profit Margin | -1,312.63% |
Debt/Equity Ratio | 0% |
How did 0HB0 perform over the long term?
See historical performance and comparison